{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:26:28Z","timestamp":1788909988431,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.vaccine.2024.126550","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T23:25:04Z","timestamp":1732663504000},"page":"126550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Effectiveness of BNT162b2 and CoronaVac against COVID-19-related severe outcomes among children and adolescents: A Brazilian nationwide cohort study"],"prefix":"10.1016","volume":"44","author":[{"given":"Eliandra da Silveira","family":"de Lima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Ot\u00e1vio Brum","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesuely Spieckert","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus H.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato T.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo A.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederico","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Comerlato","family":"Scotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2024.126550_bb0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246326","article-title":"The differential impact of pediatric COVID-19 between high-income countries and low- and middle-income countries: A systematic review of fatality and ICU admission in children worldwide","volume":"16","author":"Kitano","year":"2021","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2024.126550_bb0010","series-title":"EtR framework\u00a0: Pfizer-BioNTech COVID-19 vaccine in children aged 5\u201311 years - advisory committee on immunization practices (ACIP)","first-page":"1","volume":"2","author":"Oliver","year":"2021"},{"key":"10.1016\/j.vaccine.2024.126550_bb0015","series-title":"Epidemiology and clinical features of SARS- CoV-2 infection in children and adolescents in the pre-Omicron era: A global systematic review and meta-analysis","volume":"14","author":"Kulkarni","year":"2024"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126550_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-020-01872-8","article-title":"The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories","volume":"19","author":"Liu","year":"2021","journal-title":"BMC Med"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126550_bb0025","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2242747","article-title":"Tracking trends in COVID-19 vaccines based on 47 different vaccines: a bibliometric review","volume":"19","author":"Tao","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126550_bb0030","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents","volume":"385","author":"Frenck","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126550_bb0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2116298","article-title":"Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age","volume":"386","author":"Walter","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126550_bb0040","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3201\/eid2904.221285","article-title":"Effectiveness of BNT162b2 vaccine against omicron variant infection among children 5\u201311 years of age","volume":"29","author":"Glatman-Freedman","year":"2023","journal-title":"Israel Emerg Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126550_bb0045","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJMoa2203209","article-title":"Effectiveness of BNT162b2 vaccine against omicron in children 5 to 11 years of age","volume":"387","author":"Tan","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126550_bb0050","article-title":"Barriers and facilitators of childhood COVID-19 vaccination among parents: a systematic review","volume":"24","author":"Khan","year":"2022","journal-title":"Front Pediatr"},{"issue":"31","key":"10.1016\/j.vaccine.2024.126550_bb0055","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1016\/j.vaccine.2022.04.097","article-title":"Factors affecting COVID-19 vaccine hesitancy among healthcare providers in 23 countries","volume":"40","author":"Leigh","year":"2022","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2024.126550_bb0060","article-title":"Parental attitudes and hesitancy about COVID-19 vs. routine childhood vaccinations: a National Survey. Front","volume":"13","author":"Temsah","year":"2021","journal-title":"Public Health"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126550_bb0065","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.vaccine.2023.01.047","article-title":"Unlocking infodemics and mysteries in COVID-19 vaccine hesitancy: Nexus of conspiracy beliefs, digital informational support, psychological well-being, and religious fatalism","volume":"41","author":"Hassan Raza","year":"2023","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126550_bb0075","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s12519-023-00699-6","article-title":"Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years","volume":"19","author":"Oliveira","year":"2023","journal-title":"World J Pediatr"},{"key":"10.1016\/j.vaccine.2024.126550_bb0080","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jpeds.2022.09.039","article-title":"Vaccine effectiveness against SARS-CoV-2 variants in adolescents from 15 to 90 days after second dose: a population-based test-negative case-control study","volume":"253","author":"Oliveira","year":"2023","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126550_bb0100","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/sim.5941","article-title":"Graphical assessment of internal and external calibration of logistic regression models by using loess smoothers","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2024.126550_bb0105","first-page":"e822","article-title":"Neutralization of SARS-CoV-2 omicron variant by sera from BNT162b2 or Coronavac vaccine recipients","volume":"16","author":"Lu","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126550_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jvacx.2022.100221","article-title":"Immunogenicity to SARS-CoV-2 omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster","volume":"12","author":"Chantasrisawad","year":"2022","journal-title":"Vaccine X"},{"issue":"11","key":"10.1016\/j.vaccine.2024.126550_bb0115","doi-asserted-by":"crossref","first-page":"422","DOI":"10.15585\/mmwr.mm7111e1","article-title":"Effectiveness of 2-dose BNT162b2 (Pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5\u201311 years and adolescents aged 12\u201315 years \u2014 PROTECT cohort, July 2021\u2013February 2022","volume":"71","author":"Fowlkes","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126550_bb0120","first-page":"1","article-title":"Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in adolescents aged 12\u201317 years: a systematic review and meta-analysis","volume":"19","author":"PDMC","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.126550_bb0125","series-title":"Effectiveness of BNT162b2 vaccine against omicron-SARS-CoV-2 subvariants in children 5\u201311 years of age in Quebec, Canada","first-page":"32","volume":"43","author":"Razafimandimby","year":"2024"},{"issue":"12","key":"10.1016\/j.vaccine.2024.126550_bb0130","first-page":"1","article-title":"The effect of COVID-19 vaccine to the omicron variant in children and adolescents: a systematic review and meta-analysis","volume":"10","author":"Lu","year":"2024","journal-title":"Front Public Health"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126550_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.2023-062520","article-title":"COVID-19 vaccine effectiveness among adolescents","volume":"153","author":"Poukka","year":"2024","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126550_bb0140","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S2352-4642(23)00078-0","article-title":"Safety and effectiveness of vaccines against COVID-19 in children aged 5\u201311 years: a systematic review and meta-analysis","volume":"7","author":"Piechotta","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"issue":"12","key":"10.1016\/j.vaccine.2024.126550_bb0145","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1007\/s00431-023-05216-5","article-title":"Effectiveness of COVID-19 vaccines among children and adolescents against SARS-CoV-2 variants: a meta-analysis","volume":"182","author":"Lan","year":"2023","journal-title":"Eur J Pediatr"},{"issue":"15","key":"10.1016\/j.vaccine.2024.126550_bb0150","doi-asserted-by":"crossref","first-page":"330","DOI":"10.15585\/mmwr.mm7315a2","article-title":"Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron\u2013Associated Hospitalization in Children and Adolescents \u2014 United States, 2021\u20132023","volume":"73","author":"Zambrano","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10346","key":"10.1016\/j.vaccine.2024.126550_bb0155","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0140-6736(22)01185-0","article-title":"Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5\u201311 years in Italy: a retrospective analysis of January\u2013April, 2022","volume":"400","author":"Sacco","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2024.126550_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eclinm.2022.101786","article-title":"SARS-CoV-2 seroprevalence in children worldwide: a systematic review and meta-analysis","volume":"56","author":"Naeimi","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"9","key":"10.1016\/j.vaccine.2024.126550_bb0165","doi-asserted-by":"crossref","first-page":"352","DOI":"10.15585\/mmwr.mm7109e3","volume":"71","author":"Klein","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126550_bb0170","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1001\/jamapediatrics.2023.2584","article-title":"Association of Prior COVID-19 vaccination with SARS-CoV-2 infection and death in children and young persons during the omicron variant period in Brazil","volume":"177","author":"Oliveira","year":"2023","journal-title":"JAMA Pediatr"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126550_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-32524-5","article-title":"Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the omicron period","volume":"13","author":"Florentino","year":"2022","journal-title":"Nat Commun"},{"issue":"17","key":"10.1016\/j.vaccine.2024.126550_bb0180","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.vaccine.2013.02.053","article-title":"The test-negative design for estimating influenza vaccine effectiveness","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"issue":"41","key":"10.1016\/j.vaccine.2024.126550_bb0185","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1016\/j.vaccine.2023.04.008","volume":"5","author":"Kawade","year":"2023","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126550_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.2019-0836","article-title":"Pneumococcal conjugate vaccine breakthrough infections: 2001\u20132016","volume":"145","author":"Adebanjo","year":"2020","journal-title":"Pediatrics"},{"issue":"12","key":"10.1016\/j.vaccine.2024.126550_bb0195","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S1473-3099(22)00438-8","article-title":"Waning of antibody levels induced by a 13-valent pneumococcal conjugate vaccine, using a 3 + 0 schedule, within the first year of life among children younger than 5 years in Blantyre, Malawi: an observational, population-level, serosurveillance study","volume":"22","author":"Swarthout","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2024.126550_bb0200","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/jamapediatrics.2023.4505","article-title":"Effectiveness of monovalent mRNA vaccines against omicron XBB infection in Singaporean children younger than 5 years","volume":"177","author":"Wee","year":"2023","journal-title":"JAMA Pediatr"},{"issue":"28","key":"10.1016\/j.vaccine.2024.126550_bb0205","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1016\/j.vaccine.2022.04.091","article-title":"Measuring parents\u2019 readiness to vaccinate themselves and their children against COVID-19","volume":"40","author":"Rees","year":"2022","journal-title":"Vaccine"},{"issue":"99","key":"10.1016\/j.vaccine.2024.126550_bb0210","first-page":"S28","article-title":"COVID-19 vaccination in children: a public health priority","volume":"21","author":"Da Fonseca Lima","year":"2022","journal-title":"J Pediatr (Rio J)"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24012325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24012325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T19:47:50Z","timestamp":1735674470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24012325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":38,"alternative-id":["S0264410X24012325"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126550","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of BNT162b2 and CoronaVac against COVID-19-related severe outcomes among children and adolescents: A Brazilian nationwide cohort study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126550","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126550"}}